Basecamp Research secures $140m for AI-driven therapies
UK-based Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN …
Post
-
-
European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance
The boardrooms of all European big pharma companies have issued a stark warning regarding the current competitiveness of the continent’s …
-
How China’s rise as a biopharma innovation hub is reshaping global dealmaking strategies
A new Intelligence Briefing from GlobalData Healthcare suggests that China is becoming an increasingly strategic component of international growth strategies …
-
BoomRay and Novartis sign $900m deal for radioligand therapy
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand …
-
Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal
Boehringer Ingelheim and Envisagenics have entered a research collaboration and option agreement that aims to validate tumour-specific targets for the …
-
Basecamp Research secures $140m for AI-driven therapies
UK-based Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN …
-
European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance
The boardrooms of all European big pharma companies have issued a stark warning regarding the current competitiveness of the continent’s …
-
How China’s rise as a biopharma innovation hub is reshaping global dealmaking strategies
A new Intelligence Briefing from GlobalData Healthcare suggests that China is becoming an increasingly strategic component of international growth strategies …
-
BoomRay and Novartis sign $900m deal for radioligand therapy
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand …
-
Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal
Boehringer Ingelheim and Envisagenics have entered a research collaboration and option agreement that aims to validate tumour-specific targets for the …
-
Why Most FDA Warning Letters Share a Single — and Fixable — Root Cause
When a warning letter from the U.S. Food and Drug Administration (FDA) lands on a quality leader's desk, the instinct …
-
Novo targets blockbuster-heavy 2030 but share slump signals unease
Shares in Novo have slumped despite the drugmaker outlining a five-year commercial strategy in a bid to return to winning …
-
What drives time-to-randomization in oncology trials?
In the United States, an estimated 2,041,910 new cases of cancer were diagnosed in 2025, with 618,120 people dying from …
-
Made Scientific acquires cell therapy facility in Pennsylvania, US
Made Scientific has acquired an 85,000ft² cell therapy manufacturing facility in Pennsylvania, US, from National Resilience, adding an operational site …
-
EC approves Menarini and NewAmsterdam’s obicetrapib therapies
The European Commission (EC) has granted marketing authorisation to NewAmsterdam Pharma and Menarini Group for Ubeslo (obicetrapib 10mg monotherapy) and …
